Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children
- Conditions
- HIV InfectionsTuberculosis
- Interventions
- Drug: Rifampin-containing anti-TB therapy
- Registration Number
- NCT00802802
- Brief Summary
Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years of age. This study is being conducted to look at the safety of EFV, blood levels of EFV, genetic factors that may affect blood levels of EFV, and how easy it is for infants and young children to take and tolerate EFV. This information will help recommend the best doses of EFV for children younger than 3 years of age.
- Detailed Description
An increasing number of children in resource-limited countries require treatment for both HIV and tuberculosis (TB); however, the options for antiretroviral therapy (ART) that is compatible with concurrent rifampin-containing anti-TB therapy are limited. As a result, treatment of HIV/TB-coinfected patients remains difficult with multiple drug interactions, very high pill burdens, overlapping toxicities, and possible immune reconstitution affecting treatment outcomes.
The use of EFV in adults and older children has allowed them to maintain their non-nucleoside reverse transcriptase inhibitor (NNRTI) backbone while receiving TB therapy including rifampin. In younger children with TB/HIV coinfection, the first-line treatment recommendation has been the triple-nucleoside reverse transcriptase inhibitor (NRTI) regimen. However, this regimen has been shown to be less effective than an EFV plus NNRTI-based regimen. In addition, triple-NRTI regimens in resource-limited settings are costly and have limited data in patients with TB, and monitoring for drug-related hypersensitivity reactions is difficult. All of these factors make EFV an attractive agent for use in HIV-infected pediatric patients with and without TB coinfection. This study will evaluate the safety, tolerance, and pharmacokinetics (PKs) of EFV when administered as opened capsules to pediatric patients younger than 3 years of age, with and without concomitant rifampin-containing anti-TB therapy. This study will also investigate genetic polymorphisms, including CYP 2B6, to help establish dosing guidelines.
This study will have two cohorts that will enroll at the same time. Cohort I, Step 1 will enroll HIV-infected infants without TB coinfection who are eligible for initiation of ART. Cohort I, Step 1 will be administered EFV for up to 24 weeks. EFV dosage, in Cohort I, Step 1, will range from 50 mg to 600 mg once daily, based on weight and CYP 2B6 genotype.
Participants in Cohort I Step 1 who develop TB or TB immune reconstitution inflammatory syndrome (IRIS) and require anti-TB medications will be allowed to enroll into Cohort I, Step 2, in which they will receive rifampin-containing anti-TB therapy and a higher dose of EFV (50 mg to 800 mg) to account for the anticipated impact of rifampin on EFV PKs. If participants in Cohort I, Step 2 require more than 24 weeks of anti-TB therapy and are unable to obtain EFV capsules from in-country sources, they may remain on the study longer than 24 weeks until discontinuing anti-TB therapy, up to 36 weeks study duration.
Participants in Cohort II will be HIV/TB coinfected infants who are eligible for ART and have been treated with and tolerated a rifampin-containing anti-TB treatment regimen for at least 1 week prior to enrollment. Participants in Cohort II will be followed while taking both rifampin-containing anti-TB and EFV therapy for 24 weeks; participants unable to obtain EFV capsules from in-country sources at the conclusion of the study may remain on the study until discontinuing anti-TB therapy, up to 36 weeks study duration. An estimated 10 to 20 of these participants from Cohort II will be followed every 4 weeks on study and provided EFV until completion of TB treatment (for up to 36 weeks study duration).
Participants in both cohorts will be stratified based on age. One stratification will include children 3 months to younger than 24 months of age, and the second stratification will include children 24 months to younger than 36 months of age. Participants will then be further stratified by cytochrome P450 genotype polymorphisms, including CYP 2B6. All participants will receive an EFV-based ART regimen using the capsule formulation of EFV and two NRTIs (chosen by site investigator). EFV capsules will be opened into a small amount of compatible, familiar, and locally available food or liquid (e.g., formula, expressed breast milk, mashed banana).
Study visits will occur at screening, entry, and at Weeks 2, 4, 6, 8, 12, 16, 20, and 24; some participants may continue to have a visit every 4 weeks after Week 24 until Week 36. At most visits, participants will undergo a physical exam, give a medical history, and have blood and urine collected. At some visits, dried blood spots (DBS) will be prepared and plasma samples will be stored. The Week 2 visit will also consist of intensive PK samplings where blood will be collected prior to taking the EFV dose and at 2, 4, 8, 12, and 24 hours post-dose. Individual dose adjustments may be made based on the results from the Week 2 visit.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 67
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cohort II Efavirenz (EFV) HIV/TB-coinfected children 3 months to 36 months of age, receiving EFV, two NRTIs, and rifampin-containing anti-tuberculosis (anti-TB) therapy Cohort I, Step 2 Efavirenz (EFV) HIV-infected children from Cohort I who become coinfected with TB during the study. They will receive EFV, two NRTIs, and rifampin-containing anti-TB therapy Cohort I, Step 1 Efavirenz (EFV) HIV-infected children 3 months to 36 months of age, receiving EFV and two NRTIs Cohort I, Step 2 Rifampin-containing anti-TB therapy HIV-infected children from Cohort I who become coinfected with TB during the study. They will receive EFV, two NRTIs, and rifampin-containing anti-TB therapy Cohort II Rifampin-containing anti-TB therapy HIV/TB-coinfected children 3 months to 36 months of age, receiving EFV, two NRTIs, and rifampin-containing anti-tuberculosis (anti-TB) therapy
- Primary Outcome Measures
Name Time Method Death Measured through Week 24 Death
A safety event as defined as a Grade 4 life-threatening toxicity or Grade 4 toxicity accompanying a serious adverse event (SAE) (e.g., hospitalization) or death that is judged to be at least possibly related to EFV Measured through Week 24 A safety event as defined as a Grade 4 life-threatening toxicity or Grade 4 toxicity accompanying a serious adverse event (SAE) (e.g., hospitalization) or death that is judged to be at least possibly related to EFV
Failure to achieve the area under the curve (AUC) target range despite dose adjustment Measured through Week 24 Failure to achieve the area under the curve (AUC) target range despite dose adjustment
Any treatment-related Grade 2B rash or Grade 3 or 4 toxicity requiring permanent discontinuation of efavirenz (EFV) Measured through Week 24 Any treatment-related Grade 2B rash or Grade 3 or 4 toxicity requiring permanent discontinuation of efavirenz (EFV)
- Secondary Outcome Measures
Name Time Method A confirmed decrease (less than 1 log) from entry quantitative HIV RNA and RNA greater than 400 copies/mL Measured at Week 8 A confirmed decrease (less than 1 log) from entry quantitative HIV RNA and RNA greater than 400 copies/mL
Trial Locations
- Locations (7)
MU-JHU Research Collaboration (MUJHU CARE LTD) CRS
🇺🇬Kampala, Uganda
Byramjee Jeejeebhoy Medical College (BJMC) CRS
🇮🇳Pune, Maharashtra, India
Harare Family Care CRS
🇿🇼Harare, Zimbabwe
Soweto IMPAACT CRS
🇿🇦Johannesburg, Gauteng, South Africa
Shandukani Research CRS
🇿🇦Johannesburg, Gauteng, South Africa
Durban Paediatric HIV CRS
🇿🇦Durban, KwaZulu-Natal, South Africa
Family Clinical Research Unit (FAM-CRU) CRS
🇿🇦Tygerberg Hills, Western Cape Province, South Africa